Skip to main content

MEDP Medpace Holdings, Inc.

Healthcare

648.14 -3.87 -0.59% Close 11/2
Since 2024-12-02 +90.4%
Open
649.06
High
653.67
Low
640.00
Prev close
652.01
Volume
198.6K
Amplitude
2.10%
P/E
36.1
P/B
31.2
Revenue YoY (TTM)
+20.4%
52W 373.00 693.97

Is Medpace Holdings, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Quality: Strong, Growth: Good, Momentum: Good, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E 36.14 74th percentile Pricey
Price / book 31.18 98th percentile Expensive
Free-cash-flow yield (%) 3.66 61th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Strong ROE, TTM is Top; Operating margin, TTM is Good.
ROE, TTM (%) 88.53 94th percentile Top
Operating margin, TTM (%) 21.39 74th percentile Good
FCF margin, TTM (%) 23.52 81th percentile Top
Quality Factor Investing: A US Quality Value Backtest
Growth Good All 2 indicators are Good.
Revenue growth, TTM YoY (%) 20.35 75th percentile Good
Diluted EPS growth, TTM YoY (%) 26.07 69th percentile Good
Momentum Good 60-day return is Top; 240-day return is Good.
60-day return (%) 11.45 87th percentile Top
240-day return (%) 10.49 63th percentile Good
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 209,891,499 93th percentile Top
60-day annualized volatility (%) 29.96 34th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

Medpace Holdings, Inc. (MEDP) today

3 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Medpace Holdings, Inc. to every stock like it

AI finds several complementary traits of Medpace Holdings, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Medpace Holdings, Inc.

Medpace Holdings, Inc. (MEDP) peers and tracking

Watchlist

This page refreshes daily after the close. Add Medpace Holdings, Inc. to your watchlist to track signal changes on your next visit.

Medpace Holdings, Inc. (MEDP) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

31 historical occurrences (since 2017-12-18)

Average forward return after 52-week adjusted-price high

20-day: Win 50%, Sample 30, Median -0.09%, Excess -0.47%, Beat mkt rate 50%

60-day: Win 53.6%, Sample 28, Median +1.52%, Excess +1.54%, Beat mkt rate 64.3%

120-day: Win 64.3%, Sample 28, Median +13.98%, Excess +3.27%, Beat mkt rate 60.7%

120 days after: historical avg +8.69%

20-day -0.18%
60-day +3.47%
120-day +8.69%
20-day
60-day
120-day
Win
50%
53.6%
64.3%
Sample
30
28
28
Median
-0.09%
+1.52%
+13.98%
Excess
-0.47%
+1.54%
+3.27%
Beat mkt rate
50%
64.3%
60.7%

Over 28 occurrences, 120-day forward avg gained 8.69%, beat the market by 3.27 pts; win rate 64.3%.

Top-quintile 6-month momentum

Active · now 92.36%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
32 historical occurrences (since 2017-02-27)

Average forward return after Top-quintile 6-month momentum

20-day: Win 35.5%, Sample 31, Median -1.71%, Excess -2.89%, Beat mkt rate 32.3%

60-day: Win 58.6%, Sample 29, Median +4.09%, Excess +1.51%, Beat mkt rate 48.3%

120-day: Win 72.4%, Sample 29, Median +19.84%, Excess +6.93%, Beat mkt rate 65.5%

120 days after: historical avg +14.68%

20-day -3.08%
60-day +5.09%
120-day +14.68%
20-day
60-day
120-day
Win
35.5%
58.6%
72.4%
Sample
31
29
29
Median
-1.71%
+4.09%
+19.84%
Excess
-2.89%
+1.51%
+6.93%
Beat mkt rate
32.3%
48.3%
65.5%

Over 29 occurrences, 120-day forward avg gained 14.68%, beat the market by 6.93 pts; win rate 72.4%.

EPS surprise beat

Active · now 9.01%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest
34 historical occurrences (since 2016-11-03)

Average forward return after EPS surprise beat

20-day: Win 53.1%, Sample 32, Median +5.73%, Excess +2.74%, Beat mkt rate 53.1%

60-day: Win 65.6%, Sample 32, Median +9.39%, Excess +3.89%, Beat mkt rate 59.4%

120-day: Win 74.2%, Sample 31, Median +19.95%, Excess +11.76%, Beat mkt rate 71%

120 days after: historical avg +18.12%

20-day +3.1%
60-day +7.16%
120-day +18.12%
20-day
60-day
120-day
Win
53.1%
65.6%
74.2%
Sample
32
32
31
Median
+5.73%
+9.39%
+19.95%
Excess
+2.74%
+3.89%
+11.76%
Beat mkt rate
53.1%
59.4%
71%

Over 31 occurrences, 120-day forward avg gained 18.12%, beat the market by 11.76 pts; win rate 74.2%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 458+67.9% +59.1% 100% +47.3%
20-40 332+46% +41.1% 99.7% +28.8%
40-60 You are here267+14.9% +13.7% 63.3% +3.4%
60-80 342+7.4% -1.2% 49.1% -2%
80-100 41-18.5% -18.8% 0% -32.2%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 36.14, placing it in the 55.3 own-history percentile, inside the 40-60 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+29.1%
Win rate 86.3% Excess +21%
284d
Now
+12.8%
Win rate 61.5% Excess +4%
392d
-4.4%
Win rate 39.3% Excess -11.2%
290d
60-day momentum down
+35.3%
Win rate 79.3% Excess +27.9%
455d
+8.2%
Win rate 43.2% Excess -0.6%
125d
Insufficient data
(14d)

Currently in “Middle × 60-day momentum up”: across 392 historical days, 120-day forward avg gained 12.8%, win rate 61.5%, beat the market by 4%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

16 times historically; 60-day forward avg +5.4%, win rate 62.5%, beating the market by +4.37 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.